Should grade of tracer uptake on somatostatin receptor-targeted imaging be the major determinant and break the barrier of histopathologic criteria for determining the suitability of peptide receptor radionuclide therapy?

Journal of Nuclear Medicine

Volumn 54, Issue 11, 2013, Pages 2018-2019

  Basu, Sandip ^a  

^a BHABHA ATOMIC RESEARCH CENTRE   (India)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; ETOPOSIDE; KI 67 ANTIGEN; SOMATOSTATIN RECEPTOR; RECEPTOR;

CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DRUG TUMOR LEVEL; HISTOPATHOLOGY; HUMAN; LETTER; MEDICAL DECISION MAKING; MEDICAL SOCIETY; MOLECULAR IMAGING; MOLECULARLY TARGETED THERAPY; NEUROENDOCRINE TUMOR; NUCLEAR MEDICINE; PEPTIDE RECEPTOR RADIONUCLIDE THERAPY; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY OF LIFE; TREATMENT DURATION; TREATMENT INDICATION; TREATMENT RESPONSE; HEALTH CARE ORGANIZATION; INTERNATIONAL COOPERATION; METABOLISM; METHODOLOGY; NOTE; NUCLEAR ENERGY; RADIOTHERAPY; NEUROENDOCRINE TUMORS; PROCEDURES;

HUMANS; INTERNATIONAL AGENCIES; MOLECULAR TARGETED THERAPY; NEUROENDOCRINE TUMORS; NUCLEAR ENERGY; RADIOTHERAPY; RECEPTORS, PEPTIDE; SOCIETIES, SCIENTIFIC;

EID: 84891687067     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.113.127829     Document Type: Letter

References (3)

1. Zaknun JJ, Bodei L, Mueller-Brand J, et al. The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2013;40:800-816.
2. Klimstra DS, Modlin IR, Coppola D, Lloyd RV, Suster S. The pathologic classification of neuroendocrine tumors: a review of nomenclature, grading, and staging systems. Pancreas. 2010;39:707-712.
3. Oberg K, Knigge U, Kwekkeboom D, Perren A. Neuroendocrine gastro-enteropancreatic tumors: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. ESMO Guidelines Working Group. Ann Oncol. 2012;23(suppl 7): vii124-vii130.